Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York City, NY, talks on an analysis which investigated the efficacy of teclistamab versus real-world physician’s choice of therapy in patients with triple-class exposed (TCE) relapsed/refractory (R/R) multiple myeloma. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.